Publicado 10/03/2014 01:02
- Comunicado -

Zonegran® (Zonisamide) Approved for Use in Children and Adolescents by Scottish Medicines Consortium (SMC) (y 2)

With operations in the U.S., Asia, Europe and its domestic home market of Japan, Eisai employs more than 10,000 people worldwide. From its EMEA Knowledge Centre in Hatfield, UK, Eisai has recently expanded its business operations to include Europe, the Middle East, Africa, Russia and Oceania (EMEA). Eisai EMEA has sales and marketing operations in over 20 markets, including the United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Czech Republic, Slovakia, the Netherlands, Belgium, Russia and the Middle East.

For further information please visit our web site http://www.eisai.co.uk

References

        
        1) Scottish Medical Consortium advice on Zonegran
        2) Eisai Ltd 2013. Zonegran summary of product characteristics (last updated
          October 2013)
          https://www.medicines.org.uk/emc/medicin...
        3) Stephen LJ, et al. A prospective audit of adjunctive zonismade in an everyday
          clinical setting. Epilepsy & Behavior. 2010:17;455-460
        4) Epilepsy Scotland Facts and figures available at:
          http://www.epilepsyscotland.org.uk/facts-and-figures/info_96.... (Accessed 09
          January 2014).
        5) Joint Epilepsy Council of the UK and Ireland. Epilepsy prevalence, incidence
          and other statistics. September 2011
        6) Brodie MJ. et al. Patterns of treatment response in newly diagnosed epilepsy.
          Neurology 2012:78;1548-1554
        7) Guerrini R. et al. A randomized phase III trial of adjunctive zonisamide in
          pediatric patients with partial epilepsy. Epilepsia 2013 Aug;54(8):1473-80
        8) Glauser T. et al. Updated ILAE evidence review of antiepileptic drug efficacy
          and effectiveness as initial monotherapy for epileptic seizures and syndromes.
          Epilepsia 2013 Mar;54(3):551-63
        9) Pugliatti M et al. Estimating the cost of epilepsy in Europe: A review with
          economic modeling. Epilepsia 2007:48(12)2224-2233.
          10) Epilepsy in the WHO European Region
          http://www.ibe-epilepsy.org/downloads/EURO%20Report%20160510... [Accessed 10
          April 2012].

        
        Date of preparation: February 2014
        Job code: Zonegran-UK2519

CONTACT: Media Enquiries: Tonic Life Communications, Frances Murphy/NicolaLilley , +44(0)207-798-9262 / +44-(0)207-798-9905,frances.murphy@toniclc.com , nicola.lilley@toniclc.com. Eisai Europe Ltd,Cressida Robson/Charlotte Andrews, +44(0)7908-314-155 / +44(0)7947-231-513,Cressida_Robson@eisai.net, Charlotte_Andrews@eisai.net

Comunicados

Si quieres mejorar el posicionamiento online de tu marca, ahora puedes publicar tus notas de prensa o comunicados de empresa en la sección de Comunicados de europa press

Si necesitas asesoramiento en comunicación, redacción de tus notas de prensa o ampliar la difusión de tu comunicado más allá de la página web de europa press, ponte en contacto con nosotros en comunicacion@europapress.es o en el teléfono 913592600